05.07.2021 • News

Indian Oil Approves Styrene Project

The board of Indian state-owned oil, gas and petrochemicals group Indian Oil has approved the construction of a styrene plant, the country’s first.

The facility will have a capacity of 387,000 t/y and will cost about $603 million to build. It will be built at IndianOil’s Panipat refinery in Haryana and is scheduled to go online by 2026-2027.

IndianOil said India’s styrene consumption is around 900,000 t/y and demand is expected to increase consistently over the next 15-20 years. The country has no domestic styrene capacity and the new plant will substantially reduce its dependency on foreign imports, saving about $500 million a year. All of India’s demand is currently met by imports from Singapore, the Middle East and Southeast Asia.

In February, the IndianOil board approved an expansion of its Panipat refinery to include the installation of a fluid catalytic cracking unit that would produce ethylene and propylene. The ethylene would feed the proposed styrene plant while the 514,000 t/y propylene output would feed a new PP unit.

Last month, the company entered into an agreement with the Gujarat government to build additional petrochemical plants for PP, butyl acrylate and lube oil base stock at its refinery in Vadodara. Investment costs are estimated at $3.3 billion.

Author: Elaine Burridge, Freelance Journalist

The board of Indian Oil has approved the construction of a styrene plant, the...
The board of Indian Oil has approved the construction of a styrene plant, the country’s first. The facility will have a capacity of 387,000 t/y and cost about $603 million to build. It will be sited at IndianOil’s Panipat refinery in Haryana and is due to go online by 2026-2027. (c) Tasos Mansour

Virtual Event

Outsourced Biomanufacturing
Strategic Outsourcing in Biopharmaceuticals

Outsourced Biomanufacturing

April 22, 2026 | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.